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Abstract:  
IGF-1 Receptor and Integrin cooperative signaling promotes cancer cell survival, proliferation 
and motility, but whether this influences cancer progression and therapy responses is largely 
unknown. Here we investigated the non-receptor tyrosine adhesion kinase FER, following its 
identification as a potential mediator of sensitivity to IGF-1R kinase inhibition in a functional 
siRNA screen. We found that FER and the IGF-1R co-locate in cells and can be co-
immunoprecipitated. Ectopic FER expression strongly enhanced IGF-1R expression and 
phosphorylation on tyrosines 950 and 1131. FER phosphorylated these sites in an IGF-1R 
kinase-independent manner and also enhanced IGF-1-mediated phosphorylation of SHC, and 
activation of either AKT or MAPK signaling pathways in different cells. The IGF-1R, β1 
Integrin, FER and its substrate cortactin were all observed to co-locate in cell adhesion 
complexes, the disruption of which reduced IGF-1R expression and activity. High FER 
expression correlates with phosphorylation of SHC in breast cancer cell lines and with a poor 
prognosis in patient cohorts. FER and SHC phosphorylation and IGF-1R expression could be 
suppressed with a known ALK inhibitor (AP26113) that shows high specificity for FER kinase.  
Overall, we conclude that FER-enhances IGF-1R expression, phosphorylation and signaling to 
promote cooperative growth and adhesion signaling that may facilitate cancer progression.  
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Introduction 
The Insulin-like Growth Factor-1 Receptor (IGF-1R) and its signaling pathway has a well 
described function in sustaining a transformed phenotype [1-4]. Igf-1r knockout (Igf-1r -/-) mouse 
derived fibroblasts are refractory to transformation by oncogenes [3]. The phosphorylated 
receptor recruits IRS-1, IRS-2, or SHC to activate signaling pathways that promote cell survival, 
proliferation, or motility [1, 5]. However, despite compelling evidence for IGF-1R activity in 
facilitating cancer progression, efforts to target the IGF-1R in cancer have resulted in poor 
efficacy and clinical response [2, 6, 7]. Many reasons have been proposed for this, including 
observations that expression of IGF ligands and IGF-1R may not always correlate with signaling 
activity [7-10].  This has confounded the identification of useful biomarkers for IGF-1R activity 
inhibition in cancer cells.  
Others and we have previously established that IGF-1R kinase activity and signaling output 
are modulated by adhesion-associated protein complexes [2, 5, 11]. This crosstalk contributes to 
the mitogenic, migratory and invasive phenotype of breast, lung, cervical and prostate cancer 
[11-14]. Indeed, β1 Integrin ligation enhances IGF-1R surface expression and localization to 
sites of focal adhesion in prostate cancer cells [11]. A complex of IGF-1R-with β1 Integrin that 
includes the scaffolding protein RACK1 and focal adhesion kinase, promotes MAPK pathway 
activity [5, 15]. Furthermore, adhesion-activated kinases SRC and FAK can directly 
phosphorylate IGF-1R in vitro and enhance IGF-1R-induced invasiveness of breast cancer cells 
[12, 14, 16, 17]. All of these observations indicate that the recruitment of the IGF-1R to adhesion 
complexes can significantly modify IGF-1R activation and signaling. However, it is not known 
whether adhesion signals are essential for IGF-1R activity in cancer progression or therapy 
responses. 
We addressed this question by screening for proteins that modulate the cytotoxic response 
to IGF-1R tyrosine kinase inhibition using a functional siRNA screen [18]. We identified the 
non-receptor tyrosine FES-related (FER) kinase as a mediator of sensitivity to the IGF-1R 
tyrosine kinase inhibitor, BMS-754807, in MCF-7 cells. FER, along with FES, belongs to a 
distinct subfamily of receptor tyrosine kinases that possess FES/CIP4 homology Bin-
Amphiphysin-Rvs (F-BAR) domains [19]. FER activity has been described in several cancers, 
including lung, hepatic, prostate and breast and is reported to facilitate tumorigenesis and 
chemoresistance by enhancing cell migration, invasion and proliferation [20-23]. FER has been 
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shown to interact with the EGFR, PDGFR, FLT3 and c-MET [21, 24-26] and proposed to 
facilitate crosstalk between growth factor receptors and cell-cell- or cell-matrix- adhesion 
complexes [19]. 
In this study we investigated whether FER modulates IGF-1R signaling in different cell 
lines. We found that FER associates with and enhances IGF-1R expression and activity at the 
plasma membrane and sites of cell adhesion. FER significantly increases IGF-1R 
phosphorylation on key tyrosines to enhance IGF-1-mediated activation of SHC and MAPK 
pathways in an adhesion-dependent manner. We conclude that FER kinase is an important 
modulator of IGF-1R activity in cancer cells. This may be particularly important in mesenchymal 
or migratory cancer cells where cooperative growth factor and adhesion signaling could facilitate 
cancer progression. 
 
Results  
FER associates with and enhances IGF-1R expression levels.  
We identified FER as a modifier of responses to IGF-1R kinase inhibition in an siRNA screen 
[18] which suggested that FER may modulate IGF-1R activity. A previous study using peptide 
libraries identified FER as a kinase that could phosphorylate specific tyrosines in the Insulin and 
IGF-1 Receptors [27]. Both of these observations suggested that FER could modulate IGF-1R 
activity. To investigate this we first tested whether FER and the IGF-1R interact.  Using 
proximity ligation assays (PLA) with anti-FER and IGF-1R antibodies, we observed that FER 
and IGF-1R are clearly found in proximity in MCF-7 cells (Fig. 1A). FER could also be co-
immunoprecipitated with the IGF-1R from R+ cells (mouse embryonic fibroblasts (MEFs) 
derived from igf-1r-/- mouse with IGF-1R re-expressed) (Fig. 1B).  This was evident in cells that 
were serum deprived or stimulated with IGF-1, and in the presence of an IGF-1R kinase inhibitor 
BMS-754807 that suppressed IGF-1R autophosphorylation and IGF-induced activation of AKT 
(Fig 1B bottom panel).  The IGF-1R and FER could also be co-immunoprecipitated from 
HEK293T cells that were co-transfected with IGF-1R and either wild type FER (WT), kinase-
inactive FER (KD), or a SH2 domain mutant of FER (R483Q) (Fig. 1C). Interestingly, in these 
experiments it was noted that levels of IGF-1R expression were apparently higher in cells 
transfected with FER than in vector-expressing controls.  
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We further tested the effects of FER on IGF-1R expression in HEK293T cells.  Co-
transfection of plasmids encoding FER and the IGF-1R resulted in a 6-fold increase in IGF-1R 
protein levels compared to levels in cells transfected with IGF-1R and vector controls (Fig. 1D).  
This increase in protein was not due to enhanced transcription because Igf-1r mRNA expression 
levels were lower in in cells expressing FER than in controls (Fig. 1E).  
To test whether FER kinase activity was required to enhance IGF-1R protein levels, we 
transiently expressed IGF-1R in the presence of either FER/WT or FER/KD in HEK293T cells. 
Both FER/WT and FER/KD enhanced IGF-1R protein levels (Fig. 1F). Furthermore, levels of 
both IGF-1R/WT and kinase-dead IGF-1R (IGF-1R/KD) could be increased by co-transfection 
with FER (Fig. 1G). Taken together, these data indicate that FER and IGF-1R associate in 
different cells, and that FER enhance IGF-1R protein expression and steady state levels in a 
manner that is not dependent on either IGF-1R or FER kinase activity.  
 
FER enhances phosphorylation of the IGF-1R and its signaling output.  
We next investigated whether FER influences IGF-1R phosphorylation and kinase activity by co-
expressing FER with either IGF-1R/WT or IGF-1R/KD in HEK23T cells. We observed that FER 
expression specifically enhanced phosphorylation on Y950 (in the juxtamembrane region) and 
on Y1131 (in the kinase activation loop) on both IGF-1R/WT and IGF-1R/KD (Fig. 2A). Thus, 
IGF-1R kinase activity is not necessary for FER-enhanced phosphorylation of the Y950 and 
Y1131 sites. Phosphorylation of Y1135/1136 site in the kinase activation loop was evident with 
IGF-1R/WT, in the presence of FER, but not with kinase-inactive IGF-1R/KD (Fig. 2A), 
indicating that phosphorylation on this site is dependent on IGF-1R activity.  
To exclude the possibility that the effects of FER on phosphorylation of IGF-1R/KD 
were due to endogenous, albeit low, levels of IGF1-R expression in HEK293T cells, we carried 
out similar experiments in R- cells. We observed that co-expression of FER with IGF-1R WT or 
KD also enhanced phosphorylation on Y950 and Y1131. Again, FER did not enhance 
phosphorylation on the Y1135/1136 site in IGF-1R/KD (Fig. 2B). To test whether enhanced 
phosphorylation of the IGF-1R by FER required FER kinase activity, we co-expressed the IGF-
1R/WT or IGF-1R/KD with either FER or FER/KD. These experiments demonstrated that 
enhanced phosphorylation of IGF-1R (WT or KD) on Y950 and Y1131 was observed in both 
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serum-starved and IGF-1-stimulated cells. This was entirely dependent on an active FER kinase 
because the kinase inactive FER/KD did not enhance IGF-1R phosphorylation (Fig. 2C).   
Since FER enhances phosphorylation of the IGF-1R independently of IGF-1R kinase 
activity, we next asked whether this phosphorylation enhances IGF-1 signaling responses. 
Ectopic FER expression in HEK293T cells did not alter IGF-1-stimulated activation of the PI3-K 
pathway activation, as measured by phosphorylation of AKT on S473 (Fig. 2D). This is likely 
due to the high basal levels of AKT phosphorylation present in HEK293T cells that are not 
reduced by serum starvation, resulting in no further response to IGF-1 stimulation.  However, 
basal levels of SHC and FAK phosphorylation are low in these cells, which is consistent with 
their relatively weak adhesion to the substratum.  Overexpression of FER/WT, but not FER/KD, 
significantly increased both basal and IGF-1-stimulated phosphorylation of SHC and ERK1/2 
(Fig. 2D). Importantly, in vector control cells, IGF-1 did not induce detectable phosphorylation 
of Y239/240 on SHC, but IGF-1-induced phosphorylation on these sites was evident in the 
presence of FER expression. Phosphorylation of FAK (Y397 and Y925) and SRC (Y416) were 
also significantly enhanced by IGF-1 in FER/WT- but not in FER/KD-expressing cells (Fig. 2D).  
Overall these data demonstrate that FER enhances phosphorylation of specific 
autophosphorylation sites on the IGF-1R, in a FER kinase-dependent but IGF-1R kinase-
independent manner. This is associated with enhanced IGF-1 signaling responses. 
 
FER, IGF-1R and β1 integrin associate in adhesion complexes that enhance FER activity  
The IGF-1R has previously been demonstrated to participate in a signaling complex with β1 
Integrin to promote cell proliferation and motility [5, 15].  FER has also been reported to regulate 
β1 integrin signaling [28], so we hypothesized that FER is a component of a signaling complex 
containing Integrin and IGF-1R. In agreement with our observations in Figure 1 from PLA and 
immunoprecipitation, we observed that FER and IGF-1R strongly co-localize by co-
immunofluorescence in MCF-7 cells (Fig. 3A). Furthermore, as shown by confocal microscopy 
the majority of surface IGF-1R in these cells is present at large complexes that also contain FER 
and β1 Integrin (Fig. 3B) and vinculin (Fig. S1).  These complexes represent sites of focal cell 
adhesion. In MDA-MB-231 cells FER and the IGF-1R were also both observed to co-localize 
with β1 integrin at distinct sites of cell protrusion and adhesion (Fig. 3C).   
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We next asked whether an activated IGF-1R affects FER kinase activity, by measuring 
FER autophosphorylation on Y402 in HEK293T cells transfected with empty vector, IGF-
1R/WT or IGF-1R/KD. IGF-1 strongly promoted FER autophosphorylation in vector-expressing 
cells, which indicates that activation of endogenous IGF-1R is sufficient to enhance FER 
activity. FER autophosphorylation was further increased in cells expressing IGF-1R/WT but not 
in cells expressing IGF-1R/KD (Fig. 3D), thus confirming a requirement for activated IGF-1R in 
FER activation. Overexpression of FER/WT but not KD in HEK293T cells increased the 
phosphorylation of SHC (P-Y239/240) and ERK1/2 (P-T202/T204); without any evident effect 
on phosphorylation of AKT (Fig. 3E). FER/WT also promoted a significant increase in 
phosphorylation of the focal adhesion-associated kinases SRC (Y416) and FAK (on both Y397 
and Y925) (Fig. 3F). 
 Taken together these results demonstrate that FER and the IGF-1R are components of β1 
Integrin-anchored adhesion complexes that enhance activation and autophosphorylation of FER 
in an adhesion- and IGF-1- dependent manner. This suggests that the association of the IGF-1R 
with FER enhances cooperative IGF and adhesion signaling via the SHC, FAK and MAPK 
pathways and that these receptors may reciprocally activate each other.  
 
FER suppression reduces IGF-1R expression and proliferation, and differentially affects 
cell migration. 
Having observed clear effects of FER on enhancing IGF-1R expression, phosphorylation and 
signaling we next asked whether suppression of FER would alter IGF-1R expression and 
activity. To do this we first screened a panel of siRNAs that specifically target FER in different 
breast cell lines (Fig. S2A). We observed a consistent suppression of FER with all siRNAs tested 
(except siFER4). IGF-1R expression levels were clearly reduced by most of these siRNAs in 
MCF-7, MDA-MB-231 cells and HS57T cells and MCF10A cells (Fig. S2A).  To investigate 
this further we focused on two siRNAs (siFER2 which suppressed IGF-1R significantly and 
siFER3 which suppressed IGF-1R to a lesser extent) to further examine the effects of FER 
suppression on IGF-1R expression in all four cell lines.  Both siFER2 and 3 substantially 
decreased IGF-1R protein levels at 48 hours post transfection in MCF-7, MDA-MB-231 and 
HS578T cells (Fig. 4A), while β1 Integrins levels were largely unaffected (Fig. 4A and Fig. 
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S2B). Similar effects were observed for MCF10A cells at 48 hours (Fig. S2D) and for all cell 
lines at 72 hours post siRNA transfection (Fig. S2C and D).   
We next investigated the effects of siFER2 and 3 on IGF-1 signaling in MCF-7 and 
MDA-MB-231 cells. In MCF-7 cells FER suppression had no effect on IGF-1-induced AKT 
phosphorylation, but both siRNAs clearly reduced IGF-1-stimulated phosphorylation of ERK1/2 
(Fig. 4B). In MDA-MB-231 cells phosphorylation of ERK1/2 is generally not responsive to 
serum withdrawal or IGF-1, but IGF-1 induces strong phosphorylation of AKT. Here FER 
suppression with both siRNAs reduced IGF-1-induced phosphorylation of AKT (Fig. 4B).  These 
data indicated that FER suppression can suppress IGF-1 signaling responses. In line with this we 
observed that cell proliferation rates in MCF-7 and MDA-MB-231 cell lines were suppressed by 
both siFER2 and siFER3 (Fig. 4C). 
We next investigated the migratory potential of MDA-231 cells in Transwells with FER 
suppressed by siFER2 and siFER3. Surprisingly, we observed that siFER2 partially suppressed 
directional migration towards serum (approximately 30%) while siFER3 greatly impaired cell 
migration (by approximately 80%) (Fig. 4D).  Interestingly, we noted that the morphology of 
cells transfected with either siFER2 or siFER3 was quite different (siFER2 caused cells to 
become more spread while siFER3 caused cells to become more spindle-like. These differences 
in morphology elicited by siFER2 and 3 were consistently and reproducibly observed in all cell 
lines transfected with these siRNAs (MCF-7, MDA-MB-231, HS578T and MCF10A cells) (Fig. 
S2E).  MDA-MB-231 cell adhesion to fibronectin was impaired by siFER3, but not by siFER2 
(Fig. 4E). Thus, our data show that similar levels of FER suppression can result in different 
effects on cell morphology and migratory potential. Although we cannot explain these 
consistently different siRNA effects the data suggest they may be related to suppressing FER 
function in the formation of dynamic cell adhesion structures, such as lamellipodia, that are 
necessary for cell migration.  
Overall, we conclude that suppression of FER can reduce IGF-1R levels, IGF-1 signaling 
and cell proliferation. The data also indicate that similar suppression of FER does not correlate 
with similar effects on IGF-1R expression or cell phenotype, and FER suppression may result in 
different effects on cell morphology and migratory potential. 
 
Co-location of IGF-1R with FER in adhesion complexes enhances IGF-1R activity. 
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Next, we sought to investigate whether FER is required for IGF-1R activity in adhesion 
complexes. First we investigated the effects of FER suppression with siFER2 and siFER3 on the 
association of IGF-1R and FER with β1 Integrin in MDA-MB-231 cells. In agreement with our 
observations on cell morphology (Fig. S2E), we observed that cells transfected with siFER2 
were more spread with fewer directional lamellipodia while cells transfected with siFER3 were 
elongated and spindle like (Fig. 5A and B). While IGF-1R could be observed to co-localize with 
β1 integrin in adhesion complexes in control siNEG cells (Fig. 5A top panels), as described for 
Figure 3A and B, these structures and IGF-1R/β1Integrin co-localization were less evident in 
cells with FER suppressed (Fig 5A. B, C). As expected FER levels were suppressed by siFER2 
and 3, and less association with β1 Integrin was also observed (Fig. 5B).  In MCF-7 cells 
transfected with siFER2, cell adhesion sites appeared to be smaller and less mature with 
considerably less vinculin β1 integrin and IGF-1R present (Fig. S3A-C).  These immature 
adhesion sites were especially evident by confocal imaging of siFER2-transfected cells that were 
stained for paxillin (Fig. S3B). Taken together these data indicate that suppression of FER with 
either siFER2 or siFER3 disrupts the formation of mature cell adhesions and functional 
lamellipodia necessary for directional cell migration. 
Since siRNAs targeting FER apparently have different effects on cell morphology we 
also tested whether suppressing a well-described substrate of FER; cortical actin (cortactin, 
which has a role in both biosynthetic and recycling trafficking pathways [29-31]) had any effect 
on IGF-1R expression levels.   We observed that the IGF-1R co-localizes with cortactin at sites 
of cell adhesion in MCF-7 cells (Fig. 5D). SiRNA-mediated suppression of cortactin reduced 
IGF-1R levels in both MCF-7 and MDA-MB-231 cells (Fig. 5E, F).  This could be prevented by 
proteasome inhibition (shown for MDA-MB-231 cells in Fig. 5F).  
To further test whether cell adhesion is required for FER-enhanced IGF-1R activity we 
compared the effects of FER on IGF-1R autophosphorylation and signaling in HEK293T cells 
that were adherent or maintained in suspension. We observed that the FER-enhanced 
phosphorylation of IGF-1R/WT and IGF-1R/KD on Y1131 was completely abolished when cells 
were not allowed to adhere (Fig. 5G). As expected, the phosphorylation of SHC and FAK, 
evident in adherent cells expressing IGF-1R/WT and FER/WT, was absent in non-adherent cells 
(Fig. 5G). Phosphorylation on the Y1135/1136 site was reduced by lack of adhesion, but in 
agreement with results in Figure 2, was not affected by FER. Interestingly, the effects of lack of 
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cell adhesion on IGF-1R were accompanied by a reduction in FER autophosphorylation (Fig. 
5H). This demonstrates that adhesion signals enhance FER activity and its potentiation of IGF-
1R and SHC/ERK1/2 phosphorylation.  
 These observations suggest that FER promotes the assembly of mature cell adhesions, 
which enhances the phosphorylation and activity of the IGF-1R. 
 
FER expression strongly correlates with EMT markers in Mesenchymal-like breast cancer, 
and its activity can be suppressed by an ALK kinase inhibitor. 
FER expression was previously associated with a poor outcome in Triple Negative Breast Cancer 
(TNBC) [28]. We explored whether this may be related to FER function in enhancing IGF-1R 
and adhesion signaling in breast cancer by first analyzing available datasets from breast tumors 
and cell lines. Kaplan-Meier survival plots derived from The Cancer Genome Atlas (TCGA) data 
[32] demonstrated that high expression of FER is associated with poor relapse free survival 
(RFS) among breast cancer patients (P=0.00015; n=3951; Fig. 6A, Fig.  S4A). Following 
exclusion of systemically untreated patients, the hazard ratio (HR) rose to 1.63, while the median 
survival almost halved with high FER expression (65.1 to 34.82 months; P=0.91x10-9; Fig.  
S4A). FER expression influences the survival of patients of Grade III, estrogen receptor (ER) 
negative and HER2 positive types of breast cancer (HR: 1.79; P=0.008; median survival decrease 
from 47.52 to 27 months). Further analysis demonstrated that mesenchymal (M) and 
mesenchymal stem-like (MSL) were the subtypes most linked to high FER expression, with 
decreased median survival of MSL patients from 74 to 15.25 months (HR: 4.31; P=0.00028; Fig. 
6A). Cells of these subtypes have been described as less-differentiated and to manifest a highly 
migratory/invasive phenotype [33]. Interestingly, IGF-1R activity in tumors has also been 
associated with a mesenchymal and stem-like phenotype of cancer cells [7, 33]. 
In line with these observations, analysis of RNA-Seq expression profiles of 82 breast 
cancer cell lines extracted from the study of Marcotte et al. [34] demonstrated that migratory and 
mesenchymal breast cancer cell lines express FER at significantly higher levels than luminal cell 
lines (P<0.0001; Fig. 6B, Fig. S4C). Expression of FER was also strongly correlated with 
expression of EMT markers, including ZEB1/2, TWIST1/2, SNAI2 (SLUG) and VIM (Pearson 
R~0.4, P<0.0003; Fig. 6C, S9). We also investigated whether FER expression correlates with 
these markers in patient samples using TCGA) RNA-Seq data from 1215 breast cancer patients. 
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We found that FER expression strongly correlated with ZEB1/2 (Pearson R: 0.6), TWIST1 and 
SNAI2 and other EMT markers (Fig. S4 B-E).   
We also determined that FER expression in a panel of breast cancer cell lines could be 
positively correlated with phosphorylation of SHC (P-Y239/Y240) (Fig. 6D; S4F), noting that 
several of these cell lines expressed the p66 isoform of SHC that is associated with REDOX 
stress and more recently with coupling mechanical signals to activation of RhoA [35].  (The 
analysis of RNA sequencing (RNA-Seq) and reverse phase protein array (RPPA) data from 95 
breast cancer patients, available from TCGA, further demonstrated a positive correlation in 
phosphorylation of SHC (P-Y317; Pearson R: 0.34; p=0.0008) and SRC (P-Y416; Pearson R: 
0.27; p=0.007) and expression of FER (Fig. S4G).  
All of the in silico analyses suggested an important function for FER in breast cancer 
aggressiveness. Therefore, we next sought to test the consequences of pharmacological inhibition 
of FER in breast cancer cells. As there is no specific FER kinase inhibitor available, we opted to 
test an inhibitor of the 2 anaplastic lymphoma kinase (ALK), AP26113 (Brigatinib). This 
compound potently inhibits FER in in vitro kinase assays and was described to have FER as its 
next most selective target following ALK [36].  A similar ALK inhibitor has been reported to 
inhibit FES kinase, which is structurally similar to FER [37] (Fig. S4H). 
First, we tested AP26113 over a range of concentrations (50-500 nM) in HEK293T cells 
overexpressing FER (Fig. 6E). Concentrations as low as 50 nM, decreased FER 
autophosphorylation on Y412 by approximately 80% and also reduced FER-mediated 
phosphorylation of Y1131 in the IGF-1R. Consistent with our findings (Fig. 2) the inhibitor did 
not alter phosphorylation of Y1135/1136 in the IGF-1R (Fig 6E). Moreover, this kinase inhibitor 
suppressed phosphorylation of SHC and ERK1/2.  This indicates that AP26113 inhibits FER 
kinase activity and FER-induced signaling.  
We also tested AP26113 on breast cancers cells that express endogenous levels of FER. 
HS578T cells were chosen for these studies as a basal /mesenchymal-like/highly migratory 
breast cancer cell line with relatively high FER levels [38] (Fig 6D).  Exposure of HS578T cells 
to AP26113 (100-200 nM) resulted in inhibition of FER kinase autophosphorylation (Fig. 6F). 
Interestingly, FER levels were also suppressed. This may be due to destabilization of inactive 
FER as was previously reported [30]. AP26113 also reduced phosphorylation of SHC, SRC and 
ERK1/2, without affecting AKT phosphorylation. Phosphorylation of the IGF-1R on Y950 and 
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1131 could not be detected in these cells probably because of the reduction in IGF-1R levels. We 
also asked whether AP26113 (0.5 uM) altered the motility of HS578T cells over 15 hours in 
wound repair assays. We observed consistently impaired ability to fill the wound in the presence 
of AP26113 (Fig. 6G), and again, the drug reduced FER expression levels and phosphorylation, 
as well IGF-1R expression (Fig. 5H). Taken together, these data indicate that FER kinase activity 
and its actions in enhancing signaling pathways can be pharmacologically inhibited by the AP-
26113 inhibitor. This inhibitor is currently being tested in phase 2 clinical trials as a therapy for 
non-small cell lung cancer (ID:NCT02706626). 
 
Discussion: 
  
Cooperative IGF-1R and adhesion signaling has been proposed to facilitate cancer progression 
[2, 5, 39]. Here, we demonstrate that the non-receptor tyrosine kinase FER can regulate IGF-1R 
expression levels, activity, and adhesion-dependent signaling.  FER has been reported to play a 
role in crosstalk between different receptor systems including cell-cell and cell-matrix complexes 
[19, 20]. Our findings (summarized in the model in Figure 7) indicate that FER acts as an 
important node in such crosstalk between Integrin and IGF-1R signaling and that FER can be 
reciprocally activated by both IGF-1 and adhesion signaling.  
Here we show that FER and the IGF-1R strongly co-localize in cells, and interaction that 
does not require either FER or IGF-1R kinase activity. However, this interaction is essential for 
FER-enhanced IGF-1R phosphorylation and signaling. FER-induced phosphorylation of IGF-1R 
requires cell adhesion signals. It has been reported that FER regulates cellular distribution of 
Integrins by downregulating surface expression of α6 and β1 Integrins [20]. Cooperation of 
growth factor receptors with different Integrin heterodimers may positively or negatively impact 
growth factor activation and signaling [40]. Hence, the modulation of surface expression of 
different Integrin subunits can alter the growth factor signal. FER could facilitate IGF-1R 
association with Integrin-adhesion complexes, thus enhancing its phosphorylation and signaling 
output. We observed that FER generally promotes autophosphorylation of adhesion-associated 
kinases, SRC and FAK, and these can, in turn, directly phosphorylate IGF-1R, when activated by 
Integrin-mediated cell adhesion.  
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While the role of FER in growth factor signaling has been previously documented [21, 
22, 24], this is the first report of FER enhancing the expression levels and activity of the IGF-1R. 
FAK suppression has also been reported to decreases IGF-1R steady state levels [12, 16], again 
indicating that adhesion complexes support IGF-1R expression. The stability of other growth 
factor receptors can also be enhanced by adhesion complexes. For example, c-MET stability has 
been demonstrated to be dependent on Tensin 4, an adapter that links Integrins to β actin [41]. 
Therefore, we propose that the recruitment or localization of the IGF-1R to sites of cell 
adhesions results in enhanced IGF-1R stability. This could be mediated by the F-BAR domain of 
FER, because its oligomerization facilitates the formation of lamellipodia [42, 43].  We observed 
that suppression of cortactin, a substrate of FER, reduced IGF-1R steady state levels. Cortactin 
has been previously documented to prevent ligand-induced EGFR degradation and to enhance β2 
adrenergic receptor (β2AR) recycling [29, 44]. On the other hand, FER suppression was reported 
to accelerate EGFR internalization [23]. Therefore, FER and adhesion-mediated stability of IGF-
1R could be achieved by either decreased internalization, cortactin-mediated recycling, or 
decreased IGF-1R proteostasis during biosynthesis.  It is possible that the effects of FER on 
enhancing IGF-1R expression through regulating proteostasis could be mediated by FER altering 
the glycosylation of the IGF-1R receptor, because FER has been demonstrated to regulate 
laminin-binding glycan [45]. Indeed, impaired regulation of IGF-1R proteostasis associated with 
loss of the tumour suppressor protein AIRAPL has recently been associated with myeloid cell 
transformation and leukemia [46]. The FES protein, which is closely related to FER, has also 
been associated with acute myeloid leukemia where it can be activated by FLT3 [18] to promote 
cell survival. It is interesting to speculate that FES may mediate some of its survival functions in 
myeloid leukemia by enhancing the expression or activity of the IGF-1R. This however remains 
to be tested. 
An unexpected finding of our study was that siRNA-mediated suppression of FER using 
different oligonucleotides consistently reduced FER expression to apparently similar levels while 
causing consistently different effects on cell morphology and migratory potential.  Our study and 
that of Ivanova et al. [20] analyzed FER suppression in the MDA-MB-231 breast cancer cell 
line, which displays a mesenchymal phenotype.  We noted that FER suppression with siFER2 in 
our study produced a similar phenotype to that described by Ivanova et al, with cells becoming 
more spread and less migratory. However, other siRNAs, in particular siFER3, which we also 
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studied in detail, produced different effects on cell morphology and migration. Interestingly, the 
different siRNAs produced consistently similar effects on cell morphology in different cell lines, 
which suggests they selectively target certain isoforms or complexes of FER.  We could not 
establish whether different isoforms were implicated because we only observed changes in one 
protein with the available antibody. However, our data and previous reports on FER function in 
cell adhesion complexes indicate that the alterations in cell morphology elicited by siFER2 and 
siFER3 are both consistent with disrupting the formation of lammelipodia. One predicted 
outcome is that cells would become more spread cells with weak adhesions and lack of 
directional lamellipodia (observed with siFER2) and a second is that cells may not properly form 
lamellipodia (observed with siFER3). An additional possibility, suggested by the high levels of 
p66SHC observed in breast cancer cell lines that also express FER highly, is that p66SHC-
mediated activation of the RhoA pathway in fillopodia [35] may be affected by FER suppression.  
Overall, our observations illustrate that the use of selective siRNAs or shRNAs to investigate the 
physiological respones to FER suppression is not entirely straightforward.  
A previous report demonstrated that that FER expression is associated with aggressive 
breast cancer in patients (n=485) and inversely correlates with progression-free survival of 
ovarian cancer patients [24] [20]. Here, we analyzed a large subset of TCGA clinical survival 
data, ehich also shows that high FER expression (by RNA-Seq) correlates with poor relapse-free 
survival in breast cancer patients (n=3951). High expression of FER particularly increases the 
hazard ratio in the mesenchymal-subtype cohort of breast cancer patients (HR: 4.31). In support 
of this, we observed that mesenchymal/highly migratory breast cancer cells express FER at 
significantly higher level than their counterparts. Considering the strong effects of ectopic FER 
expression on IGF-1R phosphorylation, we propose that FER could mediate potentiation of IGF-
1 signaling, particularly in cancers with an EMT or stem-like phenotype. This is consistent with 
the observation that IGF-1R expression and activation may be elevated in breast cancer stem 
cells [33]. IGF-1R activity has also been implicated in the self-renewal of lung adenocarcinoma 
and chemoresistant colon cancer stem cells [33], and may also facilitate the EMT transition of 
breast, colon, prostate and lung cancer cells [2, 12, 47, 48]. 
As described here and elsewhere, the role of FER in supporting an invasive phenotype 
highlightes the need to develop  specific FER kinase inhibitors. Our results lead us to propose 
that AP11236, which inhibits FER kinase and signaling at nanomolar concentration, is an  
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excellent candidate. AP1123 was developed as an anaplastic lymphoma kinase (ALK) inhibitor 
and is in clinical trials phase 2 for non-small cell lung cancer (Brigatinib; ID: NCT02706626). 
TAE684, a similar ALK-inhibitor has been reported recently to target FES that possesses a 
kinase domain highly homologous to FER [37]. Importantly, we observed that the residues 
required for interaction between TAE684 and FES kinase, that were identified by X-ray 
crystallography [37], are conserved in FER kinase. Inhibition of FER using AP26113 may 
present a useful therapeutic approach for mesenchymal-type breast cancers.  In support of this 
concept, a tyrosine kinase inhibitor, PKC412 that was shown to specifically target a panel of 
post-EMT breast cancer cells mainly acts through inhibition of SYK and FER [49].  
The ability of FER to mediate adhesion enhanced-phosphorylation of catalytically active 
or inactive IGF-1R, and IGF-1R in the presence of IGF-1R TKI (data not shown) could also 
provide a mechanistic explanation for the lack of efficacy of IGF-1R TKIs in the clinic.  This 
conclusion is supported by reports that co-targeting the IGF-1R with SRC and FAK in breast, 
lung and pancreatic cancer models can synergistically decrease tumor growth [12, 14, 50]. Thus, 
co-targeting IGF-1R and adhesion signaling could improve the efficacy of IGF-1R inhibitors. 
We also propose that FER is a potential biomarker for adhesion-enhanced IGF-1R activity and 
its inhibition by AP26113 could effectively target tumor cells that are addicted to cooperative 
IGF-1R and adhesion signaling. 
 
Materials and Methods 
Cell culture and IGF-1 stimulation 
MCF-7, MDA-MB-231, MDA-MB-157, HEK293T, R-/IGF-1R/WT (+ 1.5 µg/ml puromycin), 
Hs578T, R- and R+  cells were maintained in Dulbecco’s Modified Eagles Medium (DMEM). 
MDA-MB-436 cells were cultured in a 50/50 mix of Leibovitz L15/RPMI media, and CAL51 
cells in a 50/50 mix of DMEM/Hams Nutrient F12 media. HCC1806, ZR-75-1 and HCC70 cells 
were maintained in RPMI 1640. BT-549 cells were grown in RPMI 1640 with 0.023IU/ml 
Insulin.  All media were supplemented with 10% (v/v) heat inactivated Fetal Bovine Serum 
(FBS), 10 mM L-Glutamine, and 5 mg/ml penicillin/streptomycin. MCF-10A cells were cultured 
as previously described [51]. Cells were cultured at 37 °C in a humidified atmosphere at 5% 
CO2. All cells were determined to be free of mycoplasma. 
 16 
For analysis of non-adherent (suspension) cells, cells were plated in duplicate on 10cm 
plates and cultured overnight in complete medium. Cells from one plate of each cell type 
enzymatically detached for 5 min, and cells recovered by centrifugation (1000 RPM) for 5 min. 
Cells were then washed with PBS and resuspended in complete medium (10mls) in a 50ml tube 
with occasional rotation for a total of 4 h prior to harvesting for lysis.  
For analysis of IGF-1 stimulation responses, cells were cultured at seeding densities that 
allowed for an approximate 70% confluency after 20 h. Cells were incubated in serum-free 
medium for 4 h prior to stimulation with 10ng/ml IGF-1 where appropriate. To terminate 
stimulation, cells were placed on ice and washed immediately with ice-cold PBS.  
 
Immunofluorescence and Proximity Ligation Assay and Microscopy  
Cells were seeded on serum-coated 10 mm glass coverslips, washed with phosphate-buffered 
saline, fixed with 4% paraformaldehyde in PHEM buffer for 30 min at 37 °C, quenched with 50 
mM Ammonium Chloride for 15 min and permeabilized using 0.1% Triton/PHEM for 5 min. 
Cells were then blocked for 30 min using 5% donkey serum/PHEM, incubated for 1 h with the 
indicated primary antibodies diluted 1:100 (unless specifically stated otherwise in figure legends) 
in the blocking buffer and washed with PHEM buffer. This was followed by incubation with 
Alexa488- (1:200) or Cy3- (1:1000) conjugated secondary antibodies with Hoechst.  
For Duolink PLA (Sigma Aldrich) experiments, cells were fixed, quenched and permeabilized 
exactly in the same manner as for the standard immunofluorescence. Following this, cells were 
incubated with Duolink blocking buffer in in a pre-heated humidity chamber for 30 min at +37 
°C. Primary antibodies anti-IGF-1R (#3027 (1:200) or #9750 (1:100); Cell Signalling) and anti-
FER (#4268 (1:200); Cell Signalling), were diluted in the Duolink blocking buffer and incubated 
on the cells in a humidity chamber overnight. PLA anti-rabbit plus and anti-mouse minus probes 
were used to label primary antibodies. The probes were mixed and diluted 1:5 in a blocking 
buffer. The slides are incubated the slides in a pre-heated humidity chamber for 1 h at +37 °C. 
The ligation stock (1:5) with ligase (1:40) was incubated on the coverslips in a pre-heated 
humidity chamber for 30 min at +37 °C. The amplification stock (1:5) with polymerase (1:80) 
was incubated on the overslips in a pre-heated humidity chamber for 100 min at +37 °C. The 
solution was removed and coverslips dried at room temperature in the dark. Coverslips were 
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mounted onto the slides using a minimal volume of Duolink In Situ Mounting Medium with 
DAPI. 
Images were acquired using a SPOT charge-coupled device camera mounted on a Nikon 
T600 fluorescent microscope (Kingston Upon Thames, UK). For confocal microscopy, images 
were acquired using ages were acquired using Flouview FV1000 confocal laser scanning 
microscope (numerical aperture:1.4) with a ×60 oil or ×100 oil immersion objective. Maximum 
intensity projections and z-stacks were processed and analyzed in Olympus Fluoview (FV10-
ASW 4.0 Viewer) where brightness and contrast were adjusted. 
 
SDS–polyacrylamide gel electrophoresis and Western blotting 
Cellular protein extracts were prepared with a lysis buffer (NP-40 or RIPA; as described 
previously) for 30 min on ice [5]. Protein concentration was determined via Bradford Assay, and 
samples were then either denatured by boiling for 5 minutes in 5X loading buffer (2% w/v SDS, 
8% v/v glycerol, 60 mM Tris-HCL, pH 6.8, 1.2% β-mercaptoethanol, and 0.2-0.4% 
Bromophenol Blue), or carried through to immunoprecipitation studies. Proteins were resolved 
by 4–20% SDS–polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose 
membrane and blocked for 1 h at room temperature in 5% milk in Tris-buffered saline-T (20 mM 
Tris, 150 mM NaCl and 0.05% Tween 20, pH 7.6). Primary antibodies were diluted in 5% milk 
in Tris-buffered saline-T and incubated with membranes at 4 °C overnight. IRDYE-conjugated 
secondary antibodies were used for detection with the Odyssey Image Scanner System (LI-COR 
Biosciences) and the Odyssey quantification software. Where re-probes were necessary, 
membranes were incubated with stripping buffer (200 mM NaOH, 1 % SDS) for 20 min at room 
temperature. Membranes were then washed, blocked, and incubated with appropriate antibodies. 
 
Immunoprecipitation 
Cell lysates were pre-cleared using Protein G-Agarose beads with lysis buffer and inhibitors for 
1 hat 4°C at a rotor speed of 5 RPM, and were then recovered by centrifugation at 3000 RPM for 
3 min at 4°C. Primary antibodies were incubated at 4°C for 1 h. Immune complexes were 
obtained by adding 25 µl of pre-washed Protein G-Agarose beads for 1 hat 4 °C, and then 
recovered by centrifugation at 1000 RPM for 3 min at 4 °C. Immunoprecipitates were washed 
three times with ice-cold lysis buffer followed by centrifugation. 2X loading buffer was added to 
 18 
each sample prior to boiling for 5 min. Samples were separated by SDS-PAGE as described 
above.  
 
DNA Transfection and mutagenesis 
Cells were transiently transfected with pcDNA3 plasmids encoding WT or mutant IGF-1R (IGF-
1R/KD: K1003R) and pSG5 plasmids encoding FER kinase or kinase-dead FER Kinase (D743R; 
KD) or SH2-domain mutant (R483Q; SH2). The corresponding empty vector was transfected for 
each plasmid as control. Mutagenesis of pSG5 plasmid to introduce D743R (FER/KD and 
R483Q (FER/SH2) was carried out using the QuikChange Lightning site-directed mutagenesis 
kit (Agilent, #210518).  
For transfection of R- cells, cells were seeded at a density of 1.5 x 106 cells/10 cm tissue 
culture dish, in antibiotic-free medium. Eighteen hours later, cells were transfected with relevant 
DNA (10 µg) and Lipofectamine 2000 (diluted in OptiMem) per 10 cm tissue culture dish and 
then incubated at 37 °C overnight. Transfected R- cells were subsequently split in preparation for 
experiments to be carried out 48 h after transfection. MCF-7 and MDA-MB-231 cells were 
transfected in a similar manner to R- cells, except for: seeding at 1.2x 106 cells/10 cm and the use 
of Lipofectamine; For co-transfection of IGF-1R and FER in HEK 293-T cells; cells were 
transfected using Calcium Phosphate. Briefly, cells were seeded 5 h prior to transfection to give 
a confluency of 70%. 3 µg of pSG5 encoding FER, together with 1 µg of pcDNA3 IGF-1R 
expressing plasmids were added to CaCl2. The DNA/ CaCl2 mixture was then added dropwise 
to 2X HBSS at a ratio of 1:1. Samples were allowed to stand for 1-2 min after which the solution 
was distributed to the pre-seeded cells in a dropwise manner. Cells were then incubated 
overnight to allow the transfection to proceed, after which cells were reseeded for experimental 
purposes and lysed 24 h later.  
 
siRNA Transfection 
A non-targeting oligonucleotide, Silencer Negative siRNA Control #2 (AM4311) from Ambion 
(Cambridgeshire, UK) was used as a Negative Control. Individual oligos targeting human FER 
kinase: siFER2 (S100287756; CAGATAGATCCTAGTACAGAA) and siFER3 (S102622067; 
CAGAACAACTTAGTAGGATAA were obtained from Qiagen. Sequences for the other FER 
siRNAs from Qiagen tested are listed in Supplementary Table 1, as well as those of the 
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SMARTpool ON-TARGETplus FER siRNA (L-003129-00-0005), which was purchased from 
Dharmacon. Transfections were performed using a final concentration of 20 nM siRNA, except 
where otherwise noted, using RNAiMAX, according to the manufacturer’s recommendations. 
Briefly, cells were trypsinized and re-suspended in antibiotic-free culture media with serum. 
siRNA oligonucleotides were diluted in OptiMem media. RNAiMAX transfection reagent was 
added to the siRNA solutions. siRNA/RNAiMAX complex was pipetted to 6-well plate and 6.5-
8.5 x 105 cells per well were then added. Cells were allowed to adhere overnight to the tissue 
culture plate. 24 h post-transfection, the siRNA/RNAiMAX complex was removed and cells 
were reseeded for experiments.  
 
Cell Proliferation, Migration and Adhesion Assays  
Proliferation: Cells were transfected as described above and replated in triplicates 24 h post-
transfection, at a density of to 3.0x104 cells/well of a 24 well plate. Cells were collected every 24 
h after replating, up to 96 h. Media was removed, cells were washed once with PBS and fixed 
with 96% Ethanol for 10 mins, followed by staining with 0.05% crystal violet in 20% Ethanol for 
30 min. Crystal violet staining of the cells was assessed by infrared scanning using Odyssey 
Scanner and quantified using Licor Image studio Lite software (LI-COR Biosciences).  
Migration; Wound-Healing assay: A scratch-wound healing assay was used to assess migration 
of cells following the treatment with FER-i (AP26113). HS578T cells were seeded in six-well 
plates at a concentration of 3.5x105 cells/ml 24 h prior to wounding. The monolayer was 
scratched using a sterile P10 tip (Time 0 h). AP26113 was added to the cells, while DMSO at the 
appropriate volume was added to the control cells. Cells were allowed to migrate for 15 h. 
Pictures of cells were captured using a 10x objective at Time 0h and 15 h.  
Migration; Transwell Assay: Migration assays were performed using 6.5mm transwell inserts 
with 8.0 µm membrane (costar#3422; Cambridge, MA), according to the manufacturer’s 
recommendations. Briefly, 24 hr post-transfection with siNEG, siFER2 or siFER3 siRNAs, 
2x105 MDA-MB-231 cells were seeded onto the upper part of the transwell chamber in serum-
free medium, and allowed to migrate towards 10% serum in the lower well  of the chamber for 
24hr. Cells were also added to 2 additional wells without transwells to serve as cell proliferation 
controls. These controls, cells that had migrated to the underside of the transwell membrane 
(‘Membrane’), and cells that had migrated through the membrane entirely and attached to the 
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bottom of the well (‘Through migration’) were fixed and stained with 0.05% crystal violet and 
measured using an Odyssey scanner quantified using Licor Image studio Lite software (LI-COR 
Biosciences).  
Adhesion assay: The wells of a 96-well plate were coated with 100 µl of fibronectin (Sigma, UK; 
5 µg/ml) or collagen I (Gibco, Lifetechnologies, Grand Island, NY; 10 µg/ml) for 2 h at 37oC, 
The plates were washed extensively with PBS and blocked with 100 µl of 2.5% bovine serum 
albumin/well for 1 h before further washing with PBS. Cells (100 µl containing 5 × 104 cells) 
were added to each coated well in triplicate and allowed to attach for the indicated times. The 
medium was removed, the wells were washed with PBS, and attached cells were fixed with 
Methanol and stained with 0.05% Crystal Violet, scanned and quantified as described above.  
 
RNA isolation and quantitative RT–PCR 
Total RNA was isolated using the Trizol method and cDNA synthesis was carried out by reverse 
transcription with equal amounts of RNA (2 µg) using a cDNA synthesis kit (Invitrogen). 
Quantitative PCR was carried out using the LightCycler instrument; Roche Molecular 
Biochemicals (East Sussex, UK) with QuantiTect SYBR Green technology (Qiagen, Crawley, 
West Sussex, UK) using the following primers: 1) IGF-1R: Forward: 5’-
ATGTCCAGGCCAAAACAGGAT-3’; Reverse: 5’-CCTCCCACTCATCAGGAACG-3’ 2) 
FER: Forward: 5’-GCTTCAGAAACGGCCATCAC-3’; Reverse: 5’-
AGCGTCTCCATGATGAGGTG-3’. The delta–delta CT method was used to analyze data and 
determine relative mRNA expression levels 
Bioinformatic analysis 
TCGA RNA-Seq data (n=1215) was accessed from the MD-Anderson Standardised data browser 
(bioinformatics.mdanderson.org/cancer/databrowser/). Correlation of gene expression was 
calculated using Pearson’s product moment correlation coefficient (r), statistical significance was 
determined using a modified t test (p).  
To determine correlation between protein levels and RNA levels in breast cancer, an RPPA 
dataset was downloaded, TCGA patient sample ID’s were then aligned to the RNA-Seq matrix to 
ensure each pair corresponded to two different assays conducted on the same primary sample. 
Correlation was then calculated as for RNA-Seq analysis (n=95).RNA-Seq data for an extended 
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panel of breast cancer cell lines was obtained from the supplementary material of Marcotte et al. 
[34]. 
 
Kaplan-Meier (KM) Plotter Analysis  
The KM Plotter online survival analysis was used to generate Kaplan Meier plots (Szasz et al., 
2010). Gene expression data and relapse free and overall survival information are downloaded 
from GEO (Gene Expression Omnibus; Affymetrix microarrays only), EGA and TCGA. Patient 
samples were split into two groups according to median expression of FER (ID: 206412). The 
two patient cohorts are compared by a Kaplan-Meier survival plot, and the hazard ratio with 95% 
confidence intervals, median survival and logrank P value are calculated.  
 
Statistical Analysis and Densitometry 
Densitometry of Western blots was carried out by measuring the intensity of immunolabelled 
protein bands using Odyssey/Image Studio Light Software. Results were expressed as ratio of 
phospho:total protein, or where relevant as ratios to total loading controls. In order to thoroughly 
and simultaneously investigate several IGF-1R phosphorylation sites, and FER/phospho-FER 
levels, technical replicates of lysates were run in parallel on the same or separate blots. To ensure 
consistent protein loading, each blot was probed with a loading control (e.g. actin, tubulin, 
GAPDH or pan-signalling proteins such as AKT, ERK1/2 or SHC), one of which was included 
in each figure dataset as a representative of protein loading for those samples. For data analysis 
of protein expression however, the respective protein loading control for each sample on a 
particular blot was used for normalisation of protein expression. Changes in ratio of 
phospho/pan-protein levels were expressed as fold changes relative to the untreated 
control. Statistical significance was determined using Student-T-Test using Microsoft Excel or 
GraphPad Prism. Significance was classified as a P value of *<0.05, **<0.01, ***<0.001. Where 
specified, One- or Two-way-Anova (GraphPad Prism) was used to determine significance, were 
a P value of <0.05 was deemed significant. All graphs were produced using GraphPad Prism and 
are graphed using Standard Error of the Mean (SEM). 
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Figure Legends 
Figure 1.  
FER associates with IGF-1R and enhances expression levels. 
A: Proximity ligation assay (PLA) showing protein interaction between FER and IGF-1R 
in MCF-7 cells. Cells were cultured on coverslips, fixed and probed with one of two rabbit anti-
IGF-1R antibodies (#3027, top panels or #9750, bottom panels) and mouse anti-FER antibody 
(#4268), and then subjected to PLA as described in detail in the methods section. The negative 
controls are cells without primary antibody subjected to PLA. Slides were examined by confocal 
microscopy using a Zeiss LSM700 inverted confocal microscope equipped with 60x oil-
immersion objective, numerical aperture 1.4. Z-projected images of the collected Z-stack were 
performed and analyzed using the Olympus Fluoview software. Each red spot represents a single 
interaction. The presented images are maximum intensity projections of Z-stacks acquired from a 
representative of three independent experiments.  
B: Western blot analysis of co-immunoprecipitated IGF-1R and FER. The IGF-1R was 
immunoprecipitated from R+ cells that were serum-starved (-), stimulated with IGF-1 (10 min; 
10 ng/ml; +), or stimulated with IGF-1 in the presence of BMS-754807 (BMS). Beads-and-
lysates (B&L) and beads-and-antibody (B&A) controls were included as well as cell lysates from 
the immunoprecipitation inputs. Blots were probed with anti-IGF-1R and anti-FER antibodies. 
The panel underneath shows the levels of P-1135/1136 IGF-1R and P-AKT in total lysates used 
for immunoprecipitation (as controls for BMS-754807 inhibition of IGF-1R kinase activity).  
C: Western blot analysis of IGF-1R and FER co-immunoprecipitated from HEK293T cells. 
The IGF-1R was immunoprecipitated from cells that were transfected with plasmids encoding 
IGF-1R Wild Type (IGF-1R/WT (pcDNA3)), FER (WT (pSG5-FER)), FER/Kinase Dead 
(FER/KD; D743R mutant), an SH2-domain mutant of FER (R483Q; SH2), or corresponding 
empty vector plasmids (EV), 48 h post-transfection. Beads-and-lysates (B&L) and beads-and-
antibody (B&A) controls were included as well as the immunoprecipitation inputs. The panel 
below shows the levels of FER and IGF-1R in the cell lysates used for immunoprecipitation.  
D, E: FER enhances IGF-1R protein expression levels. HEK293T cells were co-transfected 
with empty vector (pcDNA3-EV; EV, x-axis on graph) or IGF-1R/WT (IGF-1R, x axis on graph) 
plus either empty vector (pSG5-EV; EV, black bars on graph) or FER/WT (FER, grey bars on 
graph), 48 h post-transfection. Cells were lysed and immunoblotted for IGF-1R and FER 
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expression with β actin as a loading control (D). Or mRNA expression of igf-1r was assessed 
48h post-transfection by RT-qPCR using igf-1r specific primers and Ubiquitin C (UBC) was 
used as a gene housekeeping control for normalization of mRNA levels (E). The graphs show 
densitometry measurements of the average fold difference +/- SEM in IGF-1R protein expression 
(D) or average fold change difference +/-SEM in igf-1r mRNA expression (E), in FER-
overexpressing cells compared with EV controls. Data are from n≥3independent experiments, a 
Two-way ANOVA with Bonferroni test was applied. 
 F: Expression of IGF-1R WT and KD are both enhanced by FER. Western blots were 
prepared with cell lysates from HEK293T cells (40 h post transfection) expressing either Empty 
Vector (pcDNA3; EV), IGF-1R/WT or Vector encoding IGF-1R/Kinase Dead (KD; K1003R 
mutant), as well as either empty vector (pSG5; EV) or FER. The blots were probed with anti-
IGF-1R or anti-FER antibodies with β actin as a loading control. The graph represents 
densitometry measurements of average fold difference in IGF-1R protein expression +/- SEM in 
cells expressing EV, IGF-1R/WT or KD, together with EV or FER from four independent 
experiments. Two-way ANOVA with Bonferroni test was applied.  
G: FER kinase activity is not required for FER-mediated increased expression of IGF-1R. 
40 h post- transfection, HEK293T cells expressing empty vector (pcDNA3; EV), IGF-1R/WT or 
IGF-1R/KD and/or empty vector control for FER (pSG5; EV), FER or FER/KD, were lysed and 
immunoblotted for IGF-1R and FER expression. Densitometry measurements of mean +/- SEM 
average fold difference in IGF-1R protein expression from three independent experiments; One-
way ANOVA with Bonferroni test was applied.  
 
Figure 2.  
FER promotes phosphorylation of WT and kinase-inactive IGF-1R and enhances signaling 
output.  
A, B: Western blotting analysis of IGF-1R phosphorylation in HEK293T (A) or R- (B) cells 
co-over-expressing: EV (-) or FER (+) with EV, IGF-1R/WT (WT) or IGF-1R/KD (KD). Cells 
were lysed 48 h after transfection and Western blots were prepared to assess levels of P-Y950, P-
Y1131, P-Y1135/1136, and total IGF-1R. The levels of total FER were assessed as a control for 
transfection efficiency. Densitometry measurements of mean +/- SEM average fold difference in 
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specific P-Y site as indicated on the x-axis in the described above conditions based on at n≥3 
independent experiments; Two-way ANOVA with Bonferroni test.  
C: Western blotting analysis of IGF-1R phosphorylation in HEK293T cells co-
overexpressing: EV, FER or FER/KD with IGF-1R/WT (WT) or IGF-1R/KD (KD). At 48 h post 
transfection, cells were serum starved for 4 h, IGF-1 -stimulated (10 min; 10 ng/ml; +) and 
subsequently lysed for Western blots to assess levels of P-Y950, P-Y1131, P-Y1135/1136, and 
total IGF-1R. FER levels were assessed as a control for transfection efficiency. 
D: Western blotting analysis of IGF-1-mediated downstream signaling pathways in 
HEK293T cells co-overexpressing: EV, FER or FER/KD with IGF-1R/WT (WT) or IGF-1R/KD 
(KD).  At 48 h post transfection, cells were serum starved for 4 h prior to IGF-1 -stimulation (10 
min; 10 ng/ml; +). Western blots were prepared to assess levels of P-SHC (Y239/Y240), P-FAK 
(Y397, Y925), P-SRC (Y416), and P-AKT (S473). The levels of total FER were assessed as a 
control for transfection efficiency. Densitometry measurements of mean +/- SEM average fold 
difference in specific P-Y proteins/total protein levels as indicated above the graph, based on n≥3 
independent experiments. Statistical analysis was performed using Two-way ANOVA with 
Bonferroni test. 
 
Figure 3. 
 
FER, IGF-1R and β1 integrin associate in adhesion complexes that enhance FER activity.  
A-B. Co-localization of IGF1R with β1 integrin and FER with β1 integrin. Confocal images 
of MCF-7 cells grown for 24 h on coverslips co-stained for FER (red) and IGF-1R (rabbit 
antibody, green; A), β1 integrin (red) and IGF-1R (mouse antibody, green; upper panels, B) and 
FER (red) and β1 integrin (green; lower panels, B) using antibodies described in methods. Co-
localization is shown by the overlap of the fluorescent labels appearing in yellow. Cells were 
imaged using an Olympus Fluoview FV1000 confocal laser scanning microscope and Z-stacks 
were acquired and analysed using Fluoview Olympus software. At least two slices were acquired 
at different Z positions (Z1-Z2). Zoomed images (a, b) are presented in their respective Z-planes. 
Individual slices were 0.5 µm thick. Scale represents 20 µm. C: MDA-MB-231 were grown on 
coverslips coated with 5 µg/cm2 collagen I for 24 h and immunofluorescence staining was 
performed. IGF-1R (mouse, Millipore) and β1-Integrin (rabbit, green) are shown in the upper 
panels and FER (mouse) and β1-Integrin (rabbit, green) shown in the lower panels. A yellow 
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signal depicts areas of co-localization of the red and green fluorescent labels. The nuclei were 
stained with Hoechst (blue). Original 40x magnification, scale bars represent 200 µm. D: FER 
phosphorylation is enhanced by cell adhesion. At 40 h post-plasmid DNA transfection, 
HEK293T cells expressing EV, IGF-1R/WT or IGF-1R/KD were serum starved for 4 h and 
stimulated with IGF-1 (10 min; 10 ng/ml;+), lysed and immunoblotted for P-Y402 FER/ FER. P-
AKT and P-ERK1/2 were used as IGF-1 treatment controls. Densitometry measurements of 
mean +/- SEM average fold difference in P-Y402 FER in the above conditions based on 3 
independent experiments; Two-way ANOVA with Bonferroni test. E, F: Western blotting 
analysis of EV, FER/WT or FER/KD overexpressing HEK293T cells. 48 h post- DNA 
transfection, cells were lysed and immunoblotted for the indicated phospho- and total protein 
levels. Densitometry measurements of mean+/- SEM average fold difference in specific P-Y 
proteins/total protein levels as indicated on the y-axis in the described above conditions based on 
n≥3 independent experiments. One-way ANOVA with Bonferroni test was applied 
 
Figure 4 
Suppression of FER with siRNA suppresses IGF-1R activity and cell proliferation, but 
variably affects migratory potential 
A: Suppression of FER with siRNAs affects IGF-1R levels: Protein expression of the 
indicated proteins was analyzed by immunoblotting in control (siNEG) cells and cells treated 
with 2 different FER siRNAs (siFER2 or 3), 48 h post-transfection. Graphs show densitometry 
measurements of mean fold difference +/- SEM of IGF-1R expression in siFER-transfected cells 
compared with siNEG controls, based on at least n=3 independent experiments; Statistical 
analysis was performed using Two-way ANOVA with Bonferroni test. B: Western blot 
analysis of IGF-1R downstream signaling in cells with FER suppressed: At 48 h post-
transfection with siNEG or FER siRNAs, MCF-7 and MDA-MB-231 cells were serum starved 
for 4 h prior to stimulation with IGF-1 (10 ng/ml), for indicated times. Cell lysates were assessed 
by SDS-PAGE and immunoblotting for expression of FER, IGF-1R, P-AKT and P-ERK and 
non-phospho controls. Graphs of mean fold difference +/- SEM of P-ERK and P-AKT 
expression are shown in the graphs, quantified by densitometry from 3 independent experiments. 
Statistical significance was analyzed by Two-way ANOVA with Bonferroni test. C. FER 
suppression causes decreased cell proliferation: 24 h post-transfection with siNEG or FER 
siRNAs, cells were plated in triplicate at the same cell number and fixed and stained with crystal 
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violet every 24 h for a further 96 h. Staining intensity at each timepoint was analyzed using an 
Odyssey scanner and densitometric measurements from 3 separate experiments +/- SEM are 
shown. Statistical significance was determined using a Two-way ANOVA with Bonferroni test. 
D: FER siRNA 2 and 3 have variable effects on migration: 24 h post-transfection, siNEG, 
siFER2 and siFER3- treated MDA-MB-231 cells were seeded onto the upper part of a transwell 
chamber in serum-free medium, and allowed to migrate towards serum for 24h. Cells that had 
migrated to the underside of the transwell membrane (‘Membrane’), and cells that had migrated 
through the membrane entirely and attached to the bottom of the well (‘Through migration’) 
were fixed and stained with crystal violet and measured using an Odyssey scanner. 
Quantification of migration was first normalized to cell proliferation (shown in graph on right), 
for each cell type. Data is shown as percentage migration, of membrane or ‘through’ migration, 
with siNEG total cell migration set as 100%. Images of the transwell membrane- and ‘through’- 
migrated cells are shown, n=1. E: siRNA3-transfected cells have decreased cell adhesion to 
fibronectin, whereas FER siRNA2 does not affect adhesion: MDA-MB-231 cells were plated 
onto fibronectin (FN; 5µg/ml) or collagen I (Col; 10µg/ml) -coated wells, 48 h post-transfection 
with siNEG or siFER2 or 3. Cells were fixed and stained with crystal violet 20, 40 or 60 min 
after plating. Quantification of adherent cells was measured using Odyssey scanning and 
densitometry. Data is presented as fold change of adhesion of siNEG cells, from 3 independent 
experiments, statistical analysis was performed using the Student’s t-test. 
 
Figure 5.  
Cell adhesion is required for FER enhanced IGF-1R activity. 
A, B: Immunofluorescence of MDA-MB-231 with suppressed FER. MDA-MB-231 were 
plated onto coverslips coated with 5 µg/cm2 collagen, 24 post-tranfection with siNEG or siFER2 
or 3. Cells were allowed to attach for 24 h, fixed and stained with IGF-1R, β1-Integrin, and FER. 
A: MDA-MB-231 with suppressed FER showing less co-localization of IGF-1R (red) with β1-
Integrin (green) in adhesion complexes indicated by a reduced yellow signal illustrated in siNEG 
merged image compared with merged images of siFER2 and siFER3. B: MDA-MB-231 cells 
transfected with siFER2 or 3 show reduced FER staining (red), whereas β 1-integrin (green) 
levels are similar. Images in A and B also illustrate differences in cell morphology between cells 
transfected with siFER2 (more spread) and siFER3 (elongated). Images were taken in 40x and 
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the scale bars represent 200 µm.C: Immunofluorescence shows cortactin and IGF-1R co-
localization in MCF-7 cells. 
MCF-7 cells grown on coverslips for 24 h were fixed and stained with combinations of anti-IGF-
R (rabbit/mouse; green) and anti-cortactin (mouse; red). Slides were imaged Olympus Fluoview 
FV1000 confocal laser scanning microscope. Z-stacks were acquired and analysed using 
Fluoview Olympus software. At least two slices were acquired at different Z positions (Z1-Z2). 
Zoomed images (a, b, c) are presented in their respective Z-planes. Individual slices were 0.5 µm 
thick. Scale represents 20 µm. 
D, E: Suppression of cortactin in MCF-7 cells reduces IGF-1R levels. Total lysates of MCF-7 
were analyzed 48 h post-transfection with negative control siRNA (siNEG) or cortactin siRNA 
(siCTN) for IGF-1R and cortactin expression. E: MDA-MB-231 cells were analyzed 24 h post-
transfection with negative control siRNA (siNEG) or cortactin siRNA (siCTN). Cells were 
immediately either cultured in the presence of DMSO (CTRL) or Bortezomib (PROTEAS-i; 30 
nM) for  24 h. Expression of IGF- 1R, FER and ubiquitin as a control for proteasome inhibition, 
were analyzed by Western blotting.  
F: Cell adhesion is required for FER-mediated IGF-1R phosphorylation. Western blotting 
analysis of IGF-1R phosphorylation and FER signaling in HEK293T cells co-overexpressing: 
EV, FER/WT, or FER/KD with IGF-1R/WT (left panels) or IGF-1R/KD (right panels) as 
indicated. 48 h post- transfection, cells were transferred into suspension culture for 2 h, 
subsequently lysed and immunoblotted to assess levels of P-IGF-1R (Y1131, Y1135/6),  IGF-
1R, P-SHC (Y239/Y240) and P-FAK (Y397) as a control of the loss of adhesion signaling. The 
levels of total FER were assessed as a control for transfection efficiency. The experiments were 
performed three times with similar results while the graph represents quantification of Y1131 
and Y1135/1136 (an average of two of these experiments). 
G: Loss of adhesion signaling decreases autophosphorylation on FER. IGF-1R/WT-
expressing HEK293T cells were treated as described above. A reduced level of P- Y402 FER 
was observed when cells were in suspension. P-Y397 FAK was used as a control for the loss of 
adhesion signal. 
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Figure 6: 
High FER expression in mesenchymal breast cancer negatively correlates with relapse-free 
survival. Pharmacological inhibition of FER kinase abolishes its signaling.  
A: Kaplan Meier plots were drawn using data accessed through KM-plotter, a publicly accessible 
interface for TGCA survival data. All data sets were assayed using probe ID: 206412. P-value, 
hazard ratio (HR) and median survival were calculated and are displayed. B: RNA-Seq analysis 
of FER mRNA expression compared in low and highly migratory or luminal, basal A, and 
mesenchymal (basal B) breast cancer cell lines (n=78), extracted from Marcotte et al. (2016). 
FER mRNA expression is plotted on a log2 scale. C: Table representing in situ analysis of 
correlation of FER and expression of several mesenchymal genes in breast cancer cell lines 
(n=82), extracted from Marcotte et al. 2016. D: Western blotting analysis of FER protein 
expression and phosphorylation of SHC in a panel of breast cancer cell lines. E: Western blotting 
analysis of effects of FER-i (AP26113) on IGF-1R/WT and EV or FER-co-expressing HEK293T 
cells. At 48 h post transfection cells were cultured with AP26113 (0-500 nM) for 2 h, 
subsequently lyzed and immunoblotted for the indicated phospho- and total protein levels. FER 
immunoblot was included as an overexpression control. F: Western blotting analysis of effects of 
FER-i (AP26113) on endogenous FER and signaling in HS578T cells. Cells were treated for 2 h 
with 0-2 µM, subsequently lyzed and immunoblotted for the indicated phospho- and total protein 
levels. G, H: Effects of FER-i on HS578T cell migration were assessed by wound healing assays 
as described in Methods. Cell were pre-treated with AP26113 prior to wounding and maintained 
in medium containing 0.5µM inhibitor for 15 h post-wounding.  Plates were photographed with 
under phase contrast at 10x magnification and the image represents one of three independent 
experiments with similar results. H: After 15 h of exposure to AP26113 cells were lyzed and 
Western blots prepared to assess levels of Y402 FER, total FER and IGF-1R.  
 
Figure 7.  
Schematic representing the role of FER in potentiation of cooperative signaling between 
IGF-1R/β1 Integrin at sites of cell adhesion.  
 
We propose that the non-receptor tyrosine kinase FER is an important signaling node in 
cooperative signaling between the IGF-1R and cell adhesion signaling. FER-IGF-1R axis has a 
direct effect on IGF-1R steady state levels, its phosphorylation and signaling output. 
(CTN – cortactin). 
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